Re: 18F-Fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in Patients with Early Biochemical Recurrence After Prostatectomy: A Prospective, Single-centre, Single-arm, Comparative Imaging Trial.
暂无分享，去创建一个
[1] N. Lawrentschuk,et al. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. , 2020, European urology.
[2] Roger Slavik,et al. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. , 2019, The Lancet. Oncology.
[3] Chong Hyun Suh,et al. Impact of 68Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis. , 2018, European urology.
[4] D. Bailey,et al. A prospective randomized multicentre study of the impact of gallium‐68 prostate‐specific membrane antigen (PSMA) PET/CT imaging for staging high‐risk prostate cancer prior to curative‐intent surgery or radiotherapy (proPSMA study): clinical trial protocol , 2018, BJU international.
[5] B. Tombal,et al. "Gotta Catch 'em All", or Do We? Pokemet Approach to Metastatic Prostate Cancer. , 2017, European urology.